资源类型

期刊论文 1254

会议视频 41

会议信息 6

会议专题 1

年份

2024 3

2023 185

2022 197

2021 221

2020 123

2019 53

2018 31

2017 63

2016 35

2015 39

2014 50

2013 44

2012 23

2011 24

2010 46

2009 31

2008 21

2007 37

2006 6

2005 7

展开 ︾

关键词

新冠病毒肺炎 11

COVID-19 9

SARS-CoV-2 7

碳中和 7

2019 5

微波散射计 5

Cu(In 4

HY-2 4

2型糖尿病 3

GPS 3

Ga)Se2 3

HY-2 卫星 3

HY-2A卫星 3

SARS 3

代谢与免疫 3

光催化 3

医学 3

工程管理 3

微波辐射计 3

展开 ︾

检索范围：

排序： 展示方式：

起病时无呼吸道症状或发热的重型或危重型COVID-19患者的临床特征及转归 Article

许娟娟, 殷峥嵘, 刘宇, 汪速飞, 段丽敏, 安義, 范金烁, 廖婷婷, 金阳, 陈建国

《工程（英文）》 2021年 第7卷 第10期   页码 1454-1460 doi: 10.1016/j.eng.2020.09.009

摘要：

以不典型症状起病的新型冠状病毒肺炎2020年1月25日至2020年2月10日期间，武汉协和医院西院共收治943例COVID-19患者，其中909例（96.4%）重型或危重型COVID-19患者中有10例（1.1%）患者在起病时无呼吸系统症状或发热最终2例患者死亡，8例患者治愈出院。8例患者从入院到出院的中位时间为24 d（IQR：13~43）。

关键词： 新型冠状病毒（SARS-CoV-2）     新型冠状病毒肺炎（COVID-19）     不典型的     临床特征    

HTML PDF 收藏

感染新型冠状病毒的2型糖尿病患者的临床特征和结果——一项回顾性研究 Article

陈滢宇, 陈剑坤, 宫晓, 荣向路, 叶得伟, 金英花, 张忠德, 李际强, 郭姣

《工程（英文）》 2020年 第6卷 第10期   页码 1170-1177 doi: 10.1016/j.eng.2020.05.017

摘要：

据报道，糖尿病及其相关的代谢性疾病是新型冠状病毒肺炎（coronavirus disease 2019, COVID-19）患者的主要合并症。其中，96名（46.2％）患者患有2型糖尿病。在COVID-19合并2型糖尿病患者中，高血压（58.3％ vs. 31.2％）、冠心病（17.1％ vs. 8.0％）和慢性肾脏病（6.2％ vs. 0％）的共存率明显高于没有2型糖尿病的COVID-COVID-19合并2型糖尿病患者的CT胸部扫描异常频率和程度显著增加，包括毛玻璃样混浊（85.6％ vs. 64.9％, P < 0.001）和双侧斑片状阴影（76.7％ vs2型糖尿病和其他代谢性疾病共存于COVID-19患者中，这可能会增加发病率并加重COVID-19的病情。血糖和脂质代谢的最佳管理是确保更好的临床结果的关键。

关键词： 新冠病毒肺炎     冠状病毒     糖尿病     临床特征     合并症    

HTML PDF 收藏

传统中药治疗新型冠状病毒肺炎的疗效及机制研究进展 Review

李霖, 吴昱铮, 王佳宝, 闫慧敏, 卢佳, 王彧, 张伯礼, 张俊华, 杨剑, 王小莹, 张敏, 李越, 苗琳, 张晗

《工程（英文）》 2022年 第19卷 第12期   页码 139-152 doi: 10.1016/j.eng.2021.08.020

摘要：

在世界范围内，中药已成功用于治疗由SARS-CoV-2 病毒引起的新型冠状病毒肺炎（COVID-19）。因此，本文结合基于中医理论的药理检测方法，梳理了具有抗病毒感染、调节免疫、改善肺损伤和肺纤维化作用的中药活性化合物以及中药方剂，并对其可能的作用靶点和信号通路进行了总结。这些研究结果表明，COVID-19 的发生发展涉及病毒与受体互作以及炎症免疫激活等错综复杂的调节机制。

关键词： 中药     SARS-CoV-2     COVID-19     抗病毒     抗炎症     免疫调节    

HTML PDF 收藏

肠道优势菌群丰度变化与COVID-19严重程度相关性的临床意义 Article

汤灵玲,顾思岚,龚忆雯,李博,鲁海峰,李强,张如洪,高翔,吴正洁,张佳颖,张园园,李兰娟

《工程（英文）》 2020年 第6卷 第10期   页码 1178-1184 doi: 10.1016/j.eng.2020.05.013

摘要：

新冠病毒肺炎（COVID-19）是一种高度传染性疾病。与H7N9感染相似，COVID-19的典型临床表现是肺炎和细胞因子风暴。

关键词： 肠道菌群     新冠病毒肺炎（COVID-19）     严重急性呼吸系统综合征冠状病毒2 （SARS-CoV-2）    

HTML PDF 收藏

ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC

《农业科学与工程前沿（英文）》 2021年 第8卷 第4期   页码 603-622 doi: 10.15302/J-FASE -2021397

摘要：

The COVID-19 infections caused by SARS-CoV-2 have resulted in millions of people being infected and thousands of deaths globally since November 2019. To date, no unique therapeutic agent has been developed to slow the progression of this pandemic. Despite possessing antiviral traits the potential of bacteriocins to combat SARS-CoV-2 infection has not been fully investigated. This review summarizes the mechanisms by which bacteriocins can be manipulated and implemented as effective virus entry blockers with infection suppression potential properties to highly transmissible viruses through comprehensive immune modulations that are potentially effective against COVID-19. These antimicrobial peptides have been suggested as effective antiviral therapeutics and therapeutic supplements to prevent rapid virus transmission. This review also provides a new insight into the cellular and molecular alterations which have made SARS-CoV-2 self-modified with diversified infection patterns. In addition, the possible applications of antimicrobial peptides through both natural and induced mechanisms in infection prevention perspectives on changeable virulence cases are comprehensively analyzed. Specific attention is given to the antiviral mechanisms of the molecules along with their integrative use with synthetic biology and nanosensor technology for rapid detection. Novel bacteriocin based therapeutics with cutting-edge technologies might be potential substitutes for existing time-consuming and expensive approaches to fight this newly emerged global threat.

 

关键词： antimicrobial proteins / antiviral profiling of bacteriocins / antiviral therapeutics / immunomodulation / nanosensor technology / mutated SARS-CoV-2    

HTML PDF 收藏

中国上海某大型方舱医院新型冠状病毒气溶胶时空分布研究 Article

江佳富, 殷喆, 李靖, 贾雷利, 和儒林, 杨文慧, 杨佶虎, 范航, 张森, 王云飞, 赵增明, 彭浩然, 李利忠, 杨益, 樊士勇, 相蓉, 郭建树, 王金金, 魏娟宁, 周凤玲, 刘丁, 赵平, 崔玉军, 刘运喜, 周冬生, 董罡

《工程（英文）》 2023年 第28卷 第9期   页码 222-233 doi: 10.1016/j.eng.2023.06.006

摘要：

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）突变频发引起的2019年新型冠状病毒肺炎（COVID-19）大流行，已在全球范围内产生严重影响然而，无论在自然环境还是实验室环境，关于SARS-CoV-2气溶胶传播可能性的详细数据仍然很少。2022年，上海COVID-19疫情期间，国家会展中心经改造迅速建成了一所大型临时方舱医院，本研究在此舱医院开展了针对SARS-CoV-2气溶胶时空分布的研究。从60个样本中获取并拼接得到ORF1ab和Spike基因序列，并比较分析为SARS-CoV-2的奥密克戎毒株，并可以分为两支。综上，该研究对大型封闭场所中SARS-CoV-2的气溶胶传播的现实情况和以患者为中心梯度递减的污染情况进行了定量描述，从而为将来方舱医院在收治管理SARS-CoV-2等其他呼吸道病毒病患者时，采取针对性的措施

关键词： 新型冠状病毒肺炎     严重急性呼吸综合征冠状病毒2     气溶胶     方舱医院     中国    

HTML PDF 收藏

利用紫外线灭活新型冠状病毒

Dana Mackenzie

《工程（英文）》 2020年 第6卷 第8期   页码 851-853 doi: 10.1016/j.eng.2020.06.009

HTML PDF 收藏

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

《医学前沿（英文）》 2023年 第17卷 第4期   页码 747-757 doi: 10.1007/s11684-022-0954-x

摘要： Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response. To this end, a study on a long-term cohort of 208 participants who have recovered from COVID-19 was conducted, and the participants were followed up at 3.3 (Visit 1), 9.2 (Visit 2), and 18.5 (Visit 3) months after SARS-CoV-2 infection. They were classified into three groups (no-vaccination (n = 54), one-dose (n = 62), and two-dose (n = 92) groups) on the basis of the administration of inactivated vaccination. The neutralizing antibody (NAb) titers against the wild-type virus continued to decrease in the no-vaccination group, but they rose significantly in the one-dose and two-dose groups, with the highest NAb titers being observed in the two-dose group at Visit 3. The NAb titers against the Delta variant for the no-vaccination, one-dose, and two-dose groups decreased by 3.3, 1.9, and 2.3 folds relative to the wild-type virus, respectively, and those against the Omicron variant decreased by 7.0, 4.0, and 3.8 folds, respectively. Similarly, the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the second vaccine dose. Results showed that the convalescents benefited from the administration of the inactivated vaccine (one or two doses), which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory B cell responses. Two doses of inactivated vaccine among COVID-19 convalescents are therefore recommended for the prevention of the COVID-19 pandemic, and vaccination guidelines and policies need to be updated.

关键词： COVID-19 convalescent     SARS-CoV-2     inactivated vaccination     neutralizing antibody     B cell response    

HTML PDF 收藏

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

《医学前沿（英文）》 2022年 第16卷 第2期   页码 185-195 doi: 10.1007/s11684-021-0913-y

摘要： The record speed at which Chinese scientists identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and shared its genomic sequence with the world, has greatly facilitated the development of coronavirus disease (COVID-19) diagnostics, drugs, and vaccines. It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year, due to the efforts of the scientific community, biopharmaceutical industry, and regulatory agencies worldwide. The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity. Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold, by increasing vaccine coverage, especially for older adults and young people, and providing timely booster doses with homologous or heterologous vaccine boosts. Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.

关键词： COVID-19     pandemics     SARS-CoV-2     vaccination    

HTML PDF 收藏

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Tangchun Wu

《医学前沿（英文）》 2020年 第14卷 第6期   页码 816-819 doi: 10.1007/s11684-020-0823-4

HTML PDF 收藏

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

《医学前沿（英文）》 2021年 第15卷 第4期   页码 644-648 doi: 10.1007/s11684-021-0847-4

摘要： The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.

关键词： neutralizing antibody     antibody cocktail     SARS-CoV-2     COVID-19     therapeutic strategy    

HTML PDF 收藏

Less attention paid to waterborne SARS-CoV-2 spreading in Beijing urban communities

《环境科学与工程前沿（英文）》 2021年 第15卷 第5期 doi: 10.1007/s11783-021-1398-2

摘要：

• A survey on individual’s perception of SARS-CoV-2 transmission was conducted.

关键词： Environmental dissemination     Risk communication     Individual perception    

HTML PDF 收藏

SARS-CoV-2 variants, immune escape, and countermeasures

《医学前沿（英文）》 2022年 第16卷 第2期   页码 196-207 doi: 10.1007/s11684-021-0906-x

摘要： Coronavirus disease 2019 (COVID-19) has become a global pandemic disease. SARS-CoV-2 variants have aroused great concern and are expected to continue spreading. Although many countries have promoted roll-out vaccination, the immune barrier has not yet been fully established, indicating that populations remain susceptible to infection. In this review, we summarize the literature on variants of concern and focus on the changes in their transmissibility, pathogenicity, and resistance to the immunity constructed by current vaccines. Furthermore, we analyzed relationships between variants and breakthrough infections, as well as the paradigm of new variants in countries with high vaccination rates. Terminating transmission, continuing to strengthen variant surveillance, and combining nonpharmaceutical intervention measures and vaccines are necessary to control these variants.

关键词： SARS-CoV-2     COVID-19     vaccine     immune escape     breakthrough     prevention    

HTML PDF 收藏

Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from

Zhengqian Li, Taotao Liu, Ning Yang, Dengyang Han, Xinning Mi, Yue Li, Kaixi Liu, Alain Vuylsteke, Hongbing Xiang, Xiangyang Guo

《医学前沿（英文）》 2020年 第14卷 第5期   页码 533-541 doi: 10.1007/s11684-020-0786-5

摘要： Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a global pandemic in only 3 months. In addition to major respiratory distress, characteristic neurological manifestations are also described, indicating that SARS-CoV-2 may be an underestimated opportunistic pathogen of the brain. Based on previous studies of neuroinvasive human respiratory coronaviruses, it is proposed that after physical contact with the nasal mucosa, laryngopharynx, trachea, lower respiratory tract, alveoli epithelium, or gastrointestinal mucosa, SARS-CoV-2 can induce intrinsic and innate immune responses in the host involving increased cytokine release, tissue damage, and high neurosusceptibility to COVID-19, especially in the hypoxic conditions caused by lung injury. In some immune-compromised individuals, the virus may invade the brain through multiple routes, such as the vasculature and peripheral nerves. Therefore, in addition to drug treatments, such as pharmaceuticals and traditional Chinese medicine, non-pharmaceutical precautions, including facemasks and hand hygiene, are critically important.

关键词： coronavirus disease 2019 (COVID-19)     SARS-CoV-2     neurological manifestations     neuroinvasion     brain    

HTML PDF 收藏

Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities: a prospective

《医学前沿（英文）》   页码 867-877 doi: 10.1007/s11684-023-0995-9

摘要： Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of inactivated vaccines is not well characterized in people with comorbidities, who are at high risk of severe infection. We compared the risk of SARS-CoV-2 infection after complete vaccination with Sinopharm/BBIBP in people with comorbidities (e.g., autoimmune diseases, cardiovascular disease, chronic lung disease, and diabetes) with healthy individuals using a Cox-proportional hazard model. In July–September 2021, a total of 10 548 people (comorbidities, 2143; healthy, 8405) receiving the complete primary series of vaccination with Sinopharm/BBIBP in Bangkok, Thailand were prospectively followed for SARS-CoV-2 infection through text messaging and telephone interviewing for 6 months. A total of 295 infections from 284 participants were found. HRs (95% CI) of individuals with any comorbidities did not increase (unadjusted, 1.02 (0.77–1.36), P = 0.89; adjusted, 1.04 (0.78–1.38), P = 0.81). HRs significantly increased in the subgroup of autoimmune diseases (unadjusted, 2.64 (1.09–6.38), P = 0.032; adjusted, 4.45 (1.83–10.83), P = 0.001) but not in cardiovascular disease, chronic lung disease, or diabetes. The protection against SARS-CoV-2 infection of the Sinopharm vaccine was similar in participants with any comorbidities vs. healthy individuals. However, the protection appeared lower in the subgroup of autoimmune diseases, which may reflect suboptimal immune responses among these people.

关键词： COVID-19     Sinopharm/BBIBP vaccine     immunocompromised patients     real-world    

HTML PDF 收藏

标题 作者 时间 类型 操作

起病时无呼吸道症状或发热的重型或危重型COVID-19患者的临床特征及转归

许娟娟, 殷峥嵘, 刘宇, 汪速飞, 段丽敏, 安義, 范金烁, 廖婷婷, 金阳, 陈建国

期刊论文

感染新型冠状病毒的2型糖尿病患者的临床特征和结果——一项回顾性研究

陈滢宇, 陈剑坤, 宫晓, 荣向路, 叶得伟, 金英花, 张忠德, 李际强, 郭姣

期刊论文

传统中药治疗新型冠状病毒肺炎的疗效及机制研究进展

李霖, 吴昱铮, 王佳宝, 闫慧敏, 卢佳, 王彧, 张伯礼, 张俊华, 杨剑, 王小莹, 张敏, 李越, 苗琳, 张晗

期刊论文

肠道优势菌群丰度变化与COVID-19严重程度相关性的临床意义

汤灵玲,顾思岚,龚忆雯,李博,鲁海峰,李强,张如洪,高翔,吴正洁,张佳颖,张园园,李兰娟

期刊论文

ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC

期刊论文

中国上海某大型方舱医院新型冠状病毒气溶胶时空分布研究

江佳富, 殷喆, 李靖, 贾雷利, 和儒林, 杨文慧, 杨佶虎, 范航, 张森, 王云飞, 赵增明, 彭浩然, 李利忠, 杨益, 樊士勇, 相蓉, 郭建树, 王金金, 魏娟宁, 周凤玲, 刘丁, 赵平, 崔玉军, 刘运喜, 周冬生, 董罡

期刊论文

利用紫外线灭活新型冠状病毒

Dana Mackenzie

期刊论文

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

期刊论文

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

期刊论文

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Tangchun Wu

期刊论文

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

期刊论文

Less attention paid to waterborne SARS-CoV-2 spreading in Beijing urban communities

期刊论文

SARS-CoV-2 variants, immune escape, and countermeasures

期刊论文

Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from

Zhengqian Li, Taotao Liu, Ning Yang, Dengyang Han, Xinning Mi, Yue Li, Kaixi Liu, Alain Vuylsteke, Hongbing Xiang, Xiangyang Guo

期刊论文

Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities: a prospective

期刊论文